• Krystal Biotech’s KB103 Receives Orphan Medicinal Product Designation in Europe
  • $3.8M Defense Grant Awarded to Develop Stem Cell Therapies for EB, Wound Care
  • NIH Agency Pioneers Collaborative Research into Rare Diseases
  • Researchers Identify a Blood Biomarker for Epidermolysis Bullosa-associated Squamous Cell Carcinoma
  • Scientists Reduce Blistering in EBA Mice by Honing In on the Immune System
  • EBA Can Lead to Acute Renal Failure, Case Report Contends
  • SYK Protein a Key Regulator of Inflammatory Response in EBA Mouse Model, Study Finds
  • Krystal Files Application to Start Clinical Trial of Gene Therapy Candidate KB103
  • Fibroblast Skin Injections Show Promise in Healing Wounds in Dystrophic Epidermolysis Bullosa Patients, Study Finds
  • Amryt Pharma Advances Lead Candidate AP101 to Global Phase 3 Trial for EB
  • Krystal Biotech to File IND Application for KB103 to Treat Dystrophic Epidermolysis Bullosa
  • Genome Sequencing and Its Clinical Potential Focus of NYC Rare Disease Day Event